HomeInvestors & MediaNews
- Joint Development of Three
Bispecific Antibodies… Acquired Global License outside China
- ABL Bio, a Korean Biotech
with Industry’s Top-rated Core Technology in Bispecific Antibody and Antibody
Drug Conjugate (ADC)
July 26, 2018 - ABL Bio formed a strategic partnership with a Chinese biotech firm I-Mab Biopharma (“I-Mab”).
With this partnership, ABL Bio will conduct joint research with I-Mab
on three Bispecific Antibodies (BsAbs) that combine PD-L1 and an undisclosed
material. Including the development costs, licenses in China, Korea, and other
countries are expected to be shared under different configurations. In
addition, ABL Bio acquired the exclusive global rights to another BsAb in
regions excluding Greater China.
BsAb shows superior efficacy to monoclonal antibody and due to its low
side effects, it reduces pain and stress for the patient. For this reason, BsAb
is expected to be the new leading immuno-oncology therapy.
Sang Hoon Lee, the founder and CEO of ABL Bio, said, “We are able to
develop the first-in-class and the best-in-class BsAb through the partnership
with I-Mab, and also to speed up the process of the development of innovative
immunotherapy.” He added, “With the strong synergy between the two firms, I
expect this partnership to be an exemplary case in the global biotech
CEO Jingwu Zang of I-Mab said, “I am excited to have joined with ABL
Bio which has the world’s best technology in BsAb. We will do our best to
develop the antibody that will lead the next-generation immuno-oncology
ABL Bio currently holds core technologies in BsAb and Antibody Drug
Conjugate (ADC), the next-generation antibody therapeutics platforms in the
area of targeted anti-cancer therapy, immuno-oncology, and Parkinson’s Disease.
For the first time in Korea, it is currently in Phase 1 clinical trial of
‘ABL-001’, the first new candidate for BsAb.
I-Mab is a leading biotech firm in developing new therapeutics and runs a highly efficient team of world-class research ability. The company is developing the industry’s best biological products in immuno-oncology and immuno-inflammation. It is also preparing to submit multiple IND (Investigational New Drug) applications in order to pursue additional clinical trials and further research in the US and China.